Diagnostic Medical Systems (FRA:DMS1) Debt-to-EBITDA : N/A (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DMS1 Diagnostic Medical Systems FRA:DMS1
67 GF Score
Price €0.99
GF Value €1.06
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Diagnostic Medical Systems Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Diagnostic Medical Systems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €8.95 Mil. Diagnostic Medical Systems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €9.78 Mil. Diagnostic Medical Systems's annualized EBITDA for the quarter that ended in Dec. 2025 was €0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Diagnostic Medical Systems's Debt-to-EBITDA or its related term are showing as below:

FRA:DMS1' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -81.51   Med: -2.03   Max: 28.6
Current: 26.68

During the past 13 years, the highest Debt-to-EBITDA Ratio of Diagnostic Medical Systems was 28.60. The lowest was -81.51. And the median was -2.03.

FRA:DMS1's Debt-to-EBITDA is ranked worse than
97.01% of 469 companies
in the Medical Devices & Instruments industry
Industry Median: 1.62 vs FRA:DMS1: 26.68

Diagnostic Medical Systems  (FRA:DMS1) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Diagnostic Medical Systems Debt-to-EBITDA Related Terms

Diagnostic Medical Systems Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Diagnostic Medical Systems's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnostic Medical Systems Debt-to-EBITDA Chart

Diagnostic Medical Systems Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.27 -5.21 -3.97 28.60 5.55

Diagnostic Medical Systems Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Dec25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 -0.97 65.55 17.89 N/A

FRA:DMS1 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison

For the Medical Devices subindustry, Diagnostic Medical Systems's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diagnostic Medical Systems Debt-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Diagnostic Medical Systems's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Diagnostic Medical Systems's Debt-to-EBITDA falls into.


FRA:DMS1
67GF Score
Diagnostic Medical Systems FRA:DMS1
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diagnostic Medical Systems Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Diagnostic Medical Systems's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.948 + 9.781) / 3.372
=5.55

Diagnostic Medical Systems's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.948 + 9.781) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.

Is Diagnostic Medical Systems (FRA:DMS1) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnostic Medical Systems stock appears to be undervalued. The current stock price of €0.99 is trading 6.6% below its estimated GF Value™ of €1.06. GuruFocus considers Diagnostic Medical Systems to be Fairly Valued.

Key valuation signals for FRA:DMS1:

  • Debt-to-EBITDA: N/A
  • GF Value™: €1.06 vs. price of €0.99 (6.6% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the FRA:DMS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diagnostic Medical Systems Business Description

Other Exchanges 0RIA:UKALDMS:France
Address 9 Avenue du Canal Philippe, Gallargues le Montueux, FRA, FR-30660
Diagnostic Medical Systems is France's company engaged in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: Radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; and the Development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine.
67GF Score

Get the complete analysis for FRA:DMS1

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.99
Price
€1.06
GF Value